<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Aman Kabra on Medium]]></title>
        <description><![CDATA[Stories by Aman Kabra on Medium]]></description>
        <link>https://medium.com/@amankabra?source=rss-3a247f8712d2------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/2*cjqETXCb_V5pS6VxGGwTnw.jpeg</url>
            <title>Stories by Aman Kabra on Medium</title>
            <link>https://medium.com/@amankabra?source=rss-3a247f8712d2------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 17:56:20 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@amankabra/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Is a “strategic roadmap” a must during product launches? Wrigley differs.]]></title>
            <link>https://medium.com/@amankabra/is-a-strategic-roadmap-a-must-during-product-launches-wrigley-differs-aea3aee1ccde?source=rss-3a247f8712d2------2</link>
            <guid isPermaLink="false">https://medium.com/p/aea3aee1ccde</guid>
            <category><![CDATA[consumer-behavior]]></category>
            <category><![CDATA[product]]></category>
            <category><![CDATA[product-management]]></category>
            <category><![CDATA[product-launch]]></category>
            <category><![CDATA[strategic-planning]]></category>
            <dc:creator><![CDATA[Aman Kabra]]></dc:creator>
            <pubDate>Mon, 15 Jun 2020 17:33:20 GMT</pubDate>
            <atom:updated>2020-06-15T17:48:09.974Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*lFAkQqNBJZwRDVyvDEE2mw.jpeg" /><figcaption>Wrigley — the story that depicts how consumer-listening is everything.</figcaption></figure><p>William Wrigley, a twenty-nine years old natural salesman, fantasized about starting up his own business. With just $32 in the pocket, Wrigley came to Chicago from Philadelphia in 1891 with an ambition to sell Wrigley’s Scouring Soap.</p><p>Wrigley immediately shifted from the soap business to selling baking powder. This time, however, he threw two packs of chewing gum free with the purchase of each can of baking powder. As sales increased, customers were attracted now more toward chewing gums instead of baking powder. Not surprisingly, Wrigley made a switch again.</p><p>The first Wrigley chewing gums, Lotta Gum and Vassar, were launched that same year. They were followed in 1893, by Juicy Fruit and Wrigley’s Spearmint. The two flavors have been with us ever since.</p><p>Follow where the consumer goes — both literally and figuratively. Be flexible.</p><p>Sources:<br><a href="https://en.wikipedia.org/wiki/Wrigley_Company">https://en.wikipedia.org/wiki/Wrigley_Company</a><br><a href="https://thinkers50.com/blog/two-innovation-stories/">https://thinkers50.com/blog/two-innovation-stories</a> (<a href="https://medium.com/u/5a44fb09efb5">Thinkers50</a>, thanks!)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=aea3aee1ccde" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Testing capacity for COVID-19 in India]]></title>
            <link>https://medium.com/covid-19-insights-by-mihm-isb/testing-capacity-for-covid-19-in-india-ce1e2e08dbb8?source=rss-3a247f8712d2------2</link>
            <guid isPermaLink="false">https://medium.com/p/ce1e2e08dbb8</guid>
            <category><![CDATA[indian-school-of-business]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[testing-labs]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[operations-management]]></category>
            <dc:creator><![CDATA[Aman Kabra]]></dc:creator>
            <pubDate>Sat, 23 May 2020 16:02:47 GMT</pubDate>
            <atom:updated>2020-05-24T06:54:09.421Z</atom:updated>
            <content:encoded><![CDATA[<h3>Testing capacity for COVID-19 in India — How ready are we for the battle?</h3><p><strong>May 1, 2020</strong></p><p><em>This article is co-authored by Prof </em><a href="https://medium.com/u/fee864fbac4a"><em>Sarang Deo</em></a><em>, </em><a href="https://medium.com/u/3a247f8712d2"><em>Aman Kabra</em></a><em> and </em><a href="https://medium.com/u/3de78358183f"><em>Hemanshu Das</em></a><em>.</em></p><p>As of May 1, 2020, the Indian Council of Medical Research (ICMR) had approved 304 government laboratories and 105 private laboratories for testing COVID-19 samples. This represents more than 66% increase compared to March 31, when only 132 government labs and 51 private labs had been approved. Despite the impressive growth in the testing infrastructure, India’s testing rate of 45 persons tested per million population as of May 1 continues to be significantly lower than that in many other countries (median testing rate in the world is 397 persons tested per million population as of May 1). Figure 1 illustrates testing rates for 62 countries whose data were available. Other countries have been coloured grey.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/673/1*w5j8mj8oD3dngKLs7V-dEA.png" /></figure><p>In this note, we attempt to obtain more insights into this situation by providing approximate estimates of the actual testing capacity of approved labs and its utilization across different states. We also use historical data to project future growth in testing volume requirement and laboratory capacity, and attempt to answer the question, “Is the projected testing capacity in the near future adequate to handle the increase in required testing volume?”</p><blockquote><strong>Methodology and assumptions</strong></blockquote><p>We built a time series model to forecast laboratory testing capacity based on two main sources of data. First, we collaborated with an international public health agency to conduct surveys of private labs on the type of installed testing equipment and their capacity in terms of the number of tests that can be performed per unit time. Second, we collected data from ICMR daily reports on the increase in the number of private and public sector labs approved for COVID-19 testing across states over time. In addition to these, we made assumptions on a few model parameters (such as lead times for procurement and testing rates) for which data were not available. We also assumed that public laboratories operate for 16 hours per day in two shifts and private laboratories are operate for 12 hours per day.</p><p>We combined the estimates of testing capacity calculated above with data on the actual number of tests conducted from the official ICMR website to calculate the current level of capacity utilization (for April last week). For forecasting capacity estimates, we assumed that the rate of lab onboarding in each state would continue to be the same as the historical rates until all available labs are onboarded. We then estimate the additional capacity required in the near future (for May 31) by forecasting testing volumes across states.</p><blockquote><strong>Current scenario</strong></blockquote><p>We begin by assessing the situation with regards to testing capacity and its utilization during the last week of April. Figure 2 shows that the testing volume increased by about 150% during this short period, from ~40,000 per day to around 60,000 per day. During the same time period, laboratory capacity increased by less than 10% from ~65,000 to ~70,000. As a consequence, capacity utilization increased substantially from 60% to 85%.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/1*iB2yQbvwLMriqKAGheoECg.png" /></figure><p>We find that there is significant heterogeneity in utilization across states (Figure 3 and Figure 4). On the one hand, capacity utilization was estimated to be as low as 12% and 19% in Telangana and Kerala, respectively, indicating the availability of substantial spare capacity in these states relative to their current testing volume. On the other hand, several states such as Madhya Pradesh, Karnataka, and Tamil Nadu were estimated to be operating at close to 100% capacity indicating that it would be difficult to increase testing rates in these states unless lab capacity was augmented soon.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/596/1*s206j9AGfHBOpEf0XIkphw.png" /></figure><p>However, capacity utilization alone is not adequate to inform whether the high (low) level of utilization implies that the state is testing aggressively (conservatively) or has low (high) installed capacity. To obtain further insight into this, we calculated the capacity and testing volume compared to the population of the states and juxtaposed these with the reported number of COVID cases (Figure 43). We find that among states with high capacity utilization, Madhya Pradesh has a testing rate of ~35 per million whereas Andhra Pradesh has a testing rate of ~135 per million. These numbers suggest that states such as Madhya Pradesh should increase their testing rate but do not have the capacity to do so. On the other hand, Kerala has one of the highest testing capacity (100 per million) but a relatively lower testing rate (20 per million), possibly as their epidemic has declined in recent days.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/615/1*mnfOjrS15MSqqhAMri1kaQ.png" /></figure><blockquote><strong>Future projections</strong></blockquote><p>In late April, ICMR had announced that it expected the nationwide testing capacity to reach 100,000 tests per day by the end of May 2020. This is in line with the projections from our model, which indicates a national-level lab capacity of ~105,000 by May 31. However, it is important to understand whether this would be adequate to meet the testing needs of the country and the amount of additional testing capacity required across different states.</p><p>We first obtained a forecast of the increase in daily testing volume up to May 31 by projecting the time trend in reported cases using doubling time and the positivity rate of the samples. Figure 5 shows the results of this analysis.</p><p>Maharashtra has recorded both the largest number of COVID-19 cases and the highest positivity rate among all states. Uttarakhand, Kerala, and Himachal Pradesh have the highest doubling time and the lowest positivity rate among all states, implying a comparatively low spread of COVID-19. Kerala and Himachal Pradesh have not been plotted in Figure 5 as their doubling time of 346 and 67 days, respectively, would dramatically skew the figure, making it illegible.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/675/1*CwiESkCEYQYb--H8jbaWeg.png" /></figure><p>We then compared our estimate for daily testing volume with that of the projected testing capacity and accordingly derived the additional capacity required to meet the testing volume.</p><p>The results of this exercise are depicted in Figure 5, which shows the additional capacity required, expressed as a percentage of projected capacity. States for which we did not have sufficient data on doubling time, positivity ratio, or positive cases have been shaded grey. States having surplus capacity, such as Kerala, have been marked as 0% and coloured with white to denote no requirement of additional capacity.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/676/1*JkEd4AJxiwcc5Sjw6lvP3w.png" /></figure><p>These estimates suggest that testing capacity needs to be scaled up dramatically across several states which have current high utilization (Figure 4). For instance, Maharashtra, which contributes the highest number of reported cases, would need to add more than 450% of its testing capacity. On the other hand, a state such as Haryana, which currently has a smaller number of reported cases but extremely limited capacity, will need to add more than 600% capacity. Kerala is one of the few states that may be equipped to handle its projected testing volume with current capacity as its reported cases have been demonstrating a decreasing trend. Also, short doubling time for COVID-19 cases for some states, such as Punjab (doubling time of 5.3 days), and Tamil Nadu (doubling time of 6 days), results in a huge testing volume projection, which would require an abnormally high additional testing capacity in these states as seen in Figure 6.</p><blockquote><strong>Recommendations</strong></blockquote><ol><li><strong>Ramping up onboarding of labs</strong>: Our analysis shows that the existing rate of increase in the onboarding of labs is not sufficient to meet the testing volume needs of the country in most states. This implies that ICMR would have to speed up its process of onboarding of labs. Private sector laboratories that have NABL accreditation for reverse transcription-polymerase chain reaction test (RT-PCR, the ‘gold standard’ frontline test for COVID-19) need to undergo training at a Virus Research and Diagnostic Laboratory (VRDL) before they can start independent testing. These laboratories must also receive onboarding approval from the VRDL trainer. Exploring possible reductions in onboarding time will help these labs operationalize sooner, thus increasing testing capacity more rapidly.<br><strong><em>(Note:</em></strong><em> In addition to equipment capacity, the availability of test kits is a possible bottleneck in testing. We collected data from domestic as well as multinational test kit manufacturers, which indicates that the availability of test kits may constrain the number of tests in the private sector after May end. The availability of testing kits will be a major testing bottleneck if manufacturers do not increase their supply in sufficient quantities.)</em></li><li><strong>Sharing capacity across states:</strong> Despite best efforts from ICMR and state governments, it may not be possible to ramp up capacity to a level where each state is self-sufficient. States such as Uttar Pradesh, Bihar, Rajasthan, and Madhya Pradesh, which have weaker health systems compared to other states may find it even more challenging to ramp up their testing capacity. Also, in some cases adding capacity to existing labs may be faster and more economical than onboarding new labs as the latter may require physical infrastructure changes and training of lab personnel. The government can work jointly with the private sector to enable sample transfers and utilize surplus capacity in adjoining states. Though the current nationwide lockdown does impose certain mobility restrictions on sample transportation across states, transit permissions can be granted to sample transporters. This will require a coordinated effort across state governments. Also, some private sector companies operate centralized models wherein samples are collected from collection centres from all parts of the country and are transported to a central testing facility via air-cargo logistics within 24 hours. Outsourcing of inter-state transportation (and testing, if needed) to such third-party private sector players can be explored for improving COVID-19 sample transport system.</li><li><strong>Leveraging other parts of the health system: </strong>Tests for<strong> </strong>Human immunodeficiency virus (HIV) and<strong> </strong>tuberculosis (TB) are conducted on machines, such as Cartridge-based nucleic acid amplification test (CBNAAT), which have the same underlying technology as that required for COVID-19 testing. The only major tweak required is the shift to COVID-19 specific testing reagents and cartridges. Channelling surplus HIV and TB testing capacities toward COVID-19 testing can augment COVID-19 testing capacity. Choosing this option requires careful coordination across different healthcare verticals such that HIV and TB testing rates are not impacted massively.</li><li><strong>Scaling up pooled testing:</strong> Pooled testing (pooling multiple samples into a single sample before being tested) can result in a multi-fold decrease in test kits consumption. However, current ICMR guidelines allow pooled testing to be done for a maximum of five samples and only in areas with a positivity rate of less than 5%. Furthermore, pooled testing will require nontrivial changes in internal lab processes and documentation (e.g., sample tracking to facilitate testing of individual samples if the pooled test is positive) and perhaps additional labour to account for these additional processing steps. Given that pooled testing is not commonly used in both private and government labs, it would be crucial to ramp up training for lab personnel to ensure that this idea is implemented at scale.</li><li><strong>Redesigning sample collection models:</strong> Low current levels of capacity utilization (Figure 4) across many states suggest other bottlenecks in the testing process beyond equipment capacity. In another study, we found that sample collection and transportation models used in many districts (on-demand transportation of one patient or one sample at a time using ambulances) severely limit testing volumes due to limited availability of ambulances and trained sample collection personnel. We estimated that an aggregation model of sample collection, wherein multiple samples are collected in a single milk run and brought to the testing lab can reduce the need for ambulances by 4X.</li></ol><p>(Note: This study was recently covered by <em>Times of India</em>. Read their report <a href="https://timesofindia.indiatimes.com/city/hyderabad/isb-need-for-rapid-ramp-up-of-covid-19-testing-capabilities/articleshow/75855884.cms">here</a>.)</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ce1e2e08dbb8" width="1" height="1" alt=""><hr><p><a href="https://medium.com/covid-19-insights-by-mihm-isb/testing-capacity-for-covid-19-in-india-ce1e2e08dbb8">Testing capacity for COVID-19 in India</a> was originally published in <a href="https://medium.com/covid-19-insights-by-mihm-isb">COVID-19 Insights by Max Institute of Healthcare Management, Indian School of Business</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>